Skip to main content
Quest Diagnostics

Characterizing Molecular Diagnostic Findings From Next-Generation Sequencing Panel Testing for Individuals With Suspected Congenital Hypothyroidism or Resistance to Thyroid Hormone

2022 ACMG (American College of Medical Genetics) Annual Clinical Genetics Meeting

March 22-26, 2022, Nashville, TN

Poster presentation: Characterizing molecular diagnostic findings from next-generation sequencing panel testing for individuals with suspected congenital hypothyroidism or resistance to thyroid hormone

Authors: Scocchia A, Gall K, Hathaway J, Taylor A, Huusko J, Bernal M, Saarinen I, Schleit J, Paananen J, Myllykangas S, Koskenvuo J

Specialties: Cardiovascular, Endocrinology, Genetics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.